164 related articles for article (PubMed ID: 30738610)
1. Treatment of a high cardiovascular risk patient with McArdle's disease with PCSK9 inhibitors.
Marco-Benedí V; Jarauta E; Pérez-Calahorra S; Bea AM; Civeira F
Clin Investig Arterioscler; 2019; 31(2):89-92. PubMed ID: 30738610
[TBL] [Abstract][Full Text] [Related]
2. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
Lüscher TF
Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
[No Abstract] [Full Text] [Related]
3. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
4. Comparison of PCSK9 Inhibitor Evolocumab vs Ezetimibe in Statin-Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects 3 (GAUSS-3) Trial.
Nissen SE; Dent-Acosta RE; Rosenson RS; Stroes E; Sattar N; Preiss D; Mancini GB; Ballantyne CM; Catapano A; Gouni-Berthold I; Stein EA; Xue A; Wasserman SM; Scott R; Thompson PD;
Clin Cardiol; 2016 Mar; 39(3):137-44. PubMed ID: 26946077
[TBL] [Abstract][Full Text] [Related]
5. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
[TBL] [Abstract][Full Text] [Related]
6. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
7. [Unmet needs: patients with statin intolerance or familial hypercholesterolemia].
Masana L; Civeira F
Clin Investig Arterioscler; 2016 May; 28 Suppl 2():22-30. PubMed ID: 27888902
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of compounds with monacolin K in a case of statins intolerance.
Parra-Virto A; Torres do Rego A; Demelo-Rodríguez P; Millán Núñez-Cortés J; Álvarez-Sala LA
Clin Investig Arterioscler; 2018; 30(6):268-270. PubMed ID: 30309697
[TBL] [Abstract][Full Text] [Related]
9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
10. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors.
Scherer DJ; Nelson AJ; Psaltis PJ; Nicholls SJ
Intern Med J; 2017 Aug; 47(8):856-865. PubMed ID: 28401639
[TBL] [Abstract][Full Text] [Related]
11. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 in cholesterol metabolism: from bench to bedside.
Reiss AB; Shah N; Muhieddine D; Zhen J; Yudkevich J; Kasselman LJ; DeLeon J
Clin Sci (Lond); 2018 Jun; 132(11):1135-1153. PubMed ID: 29895529
[TBL] [Abstract][Full Text] [Related]
13. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
14. The efficacy of anti-PCSK9 antibodies: Results from recent trials.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():9-18. PubMed ID: 29096867
[TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia.
Ortega Martínez de Victoria E
Endocrinol Diabetes Nutr; 2017; 64(7):341-344. PubMed ID: 28745604
[No Abstract] [Full Text] [Related]
16. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
17. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.
Sullivan D; Olsson AG; Scott R; Kim JB; Xue A; Gebski V; Wasserman SM; Stein EA
JAMA; 2012 Dec; 308(23):2497-506. PubMed ID: 23128163
[TBL] [Abstract][Full Text] [Related]
18. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
[TBL] [Abstract][Full Text] [Related]
19. Management of patients with statin intolerance.
Fischer S; Julius U
Atheroscler Suppl; 2017 Nov; 30():33-37. PubMed ID: 29096858
[TBL] [Abstract][Full Text] [Related]
20. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting.
Korman M; Wisløff T
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):15-22. PubMed ID: 28444187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]